Randomized controlled trial.
The aim of this study is to determine the difference in outcome in patients diagnosed with complex parapneumonic effusion (stage II) and pleural empyema (stage III) who are treated with either VATS surgery or TUS guided drainage and intrapleural therapy (fibrinolytic (Alteplase) with DNase (Pulmozyme®)) as first line treatment.
This work was supported by the Novo Nordisk Foundation (grant no.: 0065455) and Skibsreder Per Henriksen, R. og Hustrus Fond.
Ongoing
Start: 1 October 2022
End: 30 September 2028